Eiger BioPharmaceuticals, Inc. (EIGR) Social Stream
Eiger BioPharmaceuticals Inc (EIGR) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Eiger BioPharmaceuticals Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 49 weeks, EIGR's average price target has gone down $5.67.
EIGR reports an average of 318.56% for its upside potential over the past 49 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
EIGR Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for EIGR as an investment opportunity.
- EIGR has a greater upside potential (average analyst target price relative to current price) than 357.82% of all US stocks.
- In the context of all US stocks, Eiger BioPharmaceuticals Inc's number of analysts covering the stock is greater than 60.44% of them.
- In the context of Pharmaceutical Products stocks, Eiger BioPharmaceuticals Inc's variance in analysts' estimates is lower than -35.58% of them.
- In terms of how Eiger BioPharmaceuticals Inc fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 248.43% of that group.
In the Pharmaceutical Products industry, DTIL, DNAC, and DBVT are the three stocks most similar to Eiger BioPharmaceuticals Inc regarding the price target and analyst recommendation information presented here.
Is EIGR a Buy, Hold or Sell? See the POWR Ratings now!